Skip to search formSkip to main contentSkip to account menu

CMC-544

Known as: CMC544, WAY-207294, Way 207294 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Inotuzumab Ozogamicin

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2016
Review
2016
Inotuzumab ozogamicin in the management of acute lymphoblastic leukaemia
ABSTRACT Whilst most adult patients with acute lymphoblastic leukaemia will go into remission with standard induction… 
Review
2013
Review
2013
Review of Antibody-Drug Conjugates, Methods in Molecular Biology series
Antibody-drug conjugates (ADCs) represent an exciting and promising therapeutic approach for the treatment of cancers. The US… 
2011
2011
Inotuzumab ozogamicin (IO; CMC544), a CD22 monoclonal antibody attached to calicheamycin, produces complete response (CR) plus complete marrow response (mCR) of greater than 50% in refractory relapse…
6507 Background: Patients (pts) with R-R ALL have a poor prognosis. CD22 is highly expressed in ALL. IO is active in CD22… 
2011
2011
World Antibody Drug Conjugate Summit Europe
The World Antibody Drug Conjugate Summit Europe, organized by Biorbis/ Hanson Wade was held in Frankfurt, Germany on February 21… 
Highly Cited
2010
Highly Cited
2010
Phase I study of inotuzumab ozogamicin (CMC‐544) in Japanese patients with follicular lymphoma pretreated with rituximab‐based therapy
Inotuzumab ozogamicin (CMC‐544), an antibody‐targeted chemotherapeutic agent composed of an anti‐CD22 antibody conjugated to… 
2010
2010
Phase 1 Study of Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin (CMC-544) Plus Rituximab In Japanese Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Abstract 2872 Background: Inotuzumab ozogamicin (CMC-544) is a humanized anti-CD22 antibody conjugated to calicheamicin, a potent… 
2010
2010
Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin (CMC-544) + Rituximab In Relapsed DLBCL Patients Followed by Stem Cell Transplantation: Preliminary Safety and Efficacy
Abstract 2883 Background: Inotuzumab ozogamicin (CMC-544) is a humanized anti-CD22 antibody conjugated to calicheamicin, a… 
2007
2007
Reduced Effect of Inotuzumab Ozogamicin (CMC544) on P-Glycoprotein Positive Malignant B Cells and Its Restoration by Multidrug Resistance Modifiers.
Several new agents have been introduced for the treatment for B cell malignancies (BCM) to overcome resistance to rituximab… 
2005
2005
Preliminary Report of a Phase 1 Study of CMC-544, an Antibody-Targeted Chemotherapy Agent, in Patients with B-Cell Non-Hodgkin’s Lymphoma (NHL).
Introduction: CMC-544 is an antibody-targeted chemotherapy agent composed of a monoclonal antibody, which specifically targets… 
2005
2005
Targeting CD20 and CD22 with Rituximab in Combination with CMC-544 Results in Improved Anti-Tumor Activity Against Non-Hodgkin’s Lymphoma (NHL) Pre-Clinical Models.
CMC-544 is an IgG4 CD22-humanized targeted immunoconjugate of calicheamicin. Upon CD22 biding, CMC-544 internalizes inducing cell… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)